FAQ: Izotropic Corporation's $375,000 Private Placement

What is the main topic of this announcement?

Izotropic Corporation has successfully closed a non-brokered private placement, raising $375,000 by selling 1.5 million units at $0.25 per unit, with proceeds allocated for general working capital.

How much money did Izotropic raise and through what method?

The company raised $375,000 through a non-brokered private placement, selling 1.5 million units at $0.25 per unit, with each unit consisting of one common share and one transferable warrant exercisable at $0.50 for three years.

What will the proceeds from this private placement be used for?

The proceeds will be used for general working capital to support Izotropic’s operations and development of imaging-based products for breast cancer screening, diagnosis, and treatment.

Were there any insider transactions or broker involvement in this offering?

Yes, an insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.

Where can I find more information about Izotropic Corporation?

More information can be found on the company’s website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

Where can I access the latest news and updates about Izotropic?

The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF.

What is Izotropic Corporation’s business focus?

Izotropic is a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis, and treatment.

Where can I view the full press release for this announcement?

The full press release can be viewed at https://ibn.fm/qjvt4.